Syncytin-1

BE0020919ProteinHumansERVW-1

This endogenous retroviral envelope protein has retained its original fusogenic properties and participates in trophoblast fusion and the formation of a syncytium during placenta morphogenesis. It is acted on by 1 drug in DrugBank.

Gene name
ERVW-1
UniProtKB entry
Q9UQF0Swiss-Prot
Cellular location
Cell membrane
Residues / weight
538 residues · 59,866 Da
Also known as
Endogenous retrovirus group W member 1 · Env-W · Envelope polyprotein gPr73 · Enverin · ERVWE1

Resolves to

Protein
UniProtQ9UQF0UniProt nameSYCY1_HUMAN
Gene
HGNCHGNC:13525NCBI Gene30816GeneCardsERVW-1
Pharmacology
IUPHAR/GtoPdb3182KEGGhsa:30816
Structure
PDB5HA6PDB6RX1PDB8OUH
Drugs

What you can answer from here — as of September 03, 2024

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
5GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which compounds in development act on Syncytin-1, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In